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Multidrug-resistant tuberculosis (MDR-TB) has
emerged as a major threat to TB control, particularly in the
former Soviet Union. To determine levels of drug resistance
within a directly observed treatment strategy (DOTS) pro-
gram supported by Médecins Sans Frontières in two
regions in Uzbekistan and Turkmenistan, Central Asia, we
conducted a cross-sectional survey of smear-positive TB
patients in selected districts of Karakalpakstan
(Uzbekistan) and Dashoguz (Turkmenistan). High levels of
MDR-TB were found in both regions. In Karakalpakstan, 14
(13%) of 106 new patients were infected with MDR-TB; 43
(40%) of 107 previously treated patients were similarly
infected. The proportions for Dashoguz were 4% (4/105
patients) and 18% (18/98 patients), respectively. Overall,
27% of patients with positive smear results whose infec-
tions were treated through the DOTS program in
Karakalpakstan and 11% of similar patients in Dashoguz
were infected with multidrug-resistant strains of TB on
admission. These results show the need for concerted
action by the international community to contain transmis-
sion and reduce the effects of MDR-TB.
T
uberculosis (TB) has increased substantially in many
parts of the former Soviet Union, particularly in those
areas most affected by economic decline and failing health
infrastructures (1). In addition to resurgent TB, significant
proportions of multidrug-resistant TB (MDR-TB) have
been demonstrated in small pockets where drug -suscepti-
bility surveys have been conducted, and these areas have
been termed “hot spots” (2,3). This article reports the
results of a drug-susceptibility survey conducted by
Médecins Sans Frontières (MSF) in collaboration with
local ministries of health, in northwestern Uzbekistan and
northern Turkmenistan in Central Asia. These regions, in
addition to experiencing a substantial economic crisis, are
facing a severe water shortage and the desiccation of the
Aral Sea (4).
A TB treatment program based on the directly
observed treatment strategy (DOTS) (5) recommended by
the World Health Organization was introduced progres-
sively into three regions south of the Aral Sea by the
humanitarian medical aid organization, Médecins Sans
Frontières. These regions, the Republic of Karakal-
pakstan, and Khorezm Oblast in Uzbekistan and
Dashoguz Velayat in Turkmenistan (Figure 1), have a total
population of approximately 4 million people.
Implementation of DOTS started in 1998 and was com-
pleted with full coverage by late 2003. In 2002, more than
8,000 patients were registered and treated under DOTS
from the three regions. Facilities for culturing sputum and
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From the start of DOTS implementation, >10% of those
treated remained smear-positive. This finding, combined
with a dearth of information on drug resistance in Central
Asia, prompted the initiation of a drug-susceptibility sur-
vey with the aim of determining levels of resistance to both
first- and second-line anti-TB drugs and, in particular, the
levels of MDR-TB. 
The current survey was conducted in two of the regions
covered by DOTS, the Republic of Karakalpakstan in
Uzbekistan and Dashoguz Velayat in Turkmenistan.
Although adjacent, these regions are separated by an inter-
national border. Key characteristics of these regions and
countries are given in Table 1; the two regions differ in
terms of total case reporting rate and in economic status.
Methods
Study Design
The survey was designed on the basis of recommenda-
tions given in the World Health Organization/International
Union Against Tuberculosis and Lung Disease
(WHO/IUATLD) guidelines for surveillance of drug-
resistant TB (8). It was designed to be a cross-sectional
survey of smear-positive pulmonary TB patients in whom
DOTS TB treatment had been initiated in four districts in
the Autonomous Republic of Karakalpakstan in
Uzbekistan and four districts in Dashoguz Velayat in
Turkmenistan. Three of the districts in each region were
selected because they had the longest running DOTS pro-
grams in the region. The fourth district in each region was
selected as the newest district implementing DOTS before
initiation of the survey. When the survey was initiated, 7 of
the 17 districts in Karakalpakstan were implementing
DOTS TB treatment, as were 7 of the 9 districts in
Dashoguz. Although selection of districts in which to con-
duct the survey was not random, all smear-positive
patients whose TB was diagnosed in DOTS laboratories
(regardless of previous TB treatment status) from July
2001 in the selected districts were sequentially requested
to participate in the survey. Patients were excluded if they
refused to undergo DOTS treatment or if they did not
reside in one of the districts chosen in the study. Patients
defined as “chronic,” that is, patients whose TB was not
resolved after at least two courses of DOTS treatment,
were not eligible to be included in the study. Smear posi-
tivity was defined as at least one sputum sample reading
>10 bacilli/100 fields in a sputum smear by direct
microscopy. 
The objectives of the study were described to each
patient, and written informed consent was obtained before
an additional sputum sample was collected for the study.
All patients were informed that the results would not be
available to either themselves or their treating physician
and would not affect their treatment. At the time of the sur-
vey, no opportunity was available for patients to be treated
with second-line drugs under DOTS-Plus. To ensure
patient confidentiality, sputum samples and clinical infor-
mation forms were encoded with a unique survey identifi-
cation number. 
MDR-TB is defined as resistance to at least isoniazid
and rifampin. On the basis of estimated levels of 10% and
20% MDR-TB for new and retreatment cases, sample sizes
were calculated to be 81 for new cases (10%±6%, 95%
confidence limit [CL]) and 100 for re-treatment cases
(20%±7%, 95% CL). Because approximately 50% of
patients with positive smears have been previously treated,
a sample size of 100 was chosen for each category in both
regions, for a total of 400 patients. Recruitment continued
until the desired sample size was reached or surpassed in
both categories and in both regions.
Demographic and Clinical Information
Each patient who consented to participate in the survey
was interviewed by the admitting doctor in each TB facil-
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Table 1. Key characteristics of the two regions and countries included in the survey
a 
  Uzbekistan  Turkmenistan 
Population (6)  25,256,000  4,834,000 
GDP per capita (6)  U.S.$ 2,333  U.S.$ 5,269 
Health expenditure per capita (6)  U.S.$ 86  U.S.$ 286 
Estimated TB incidence rate (all cases) (7)  92/100,000/y  84/100,000/y 
Estimated smear-positive case detection (7)  44%  68% 
  Karakalpakstan  Dashoguz 
Population (2001 estimated)
b  1,549,761  1,041,372 
DOTS implementation  1998 (pilot districts)–2003 (full 
coverage) 
2000 (pilot districts)–2002 (full 
coverage) 
DOTS case notification rate (all cases)  482/100,000/y  213/100,000/y 
DOTS case notification rate (smear-positive cases)  192/100,000/year  89/100,000/year 
% of smear-positive cases previously treated (2002)  55  53 
Success rate (new smear-positive cases registered in 2001)  68%  82% 
aGDP, gross domestic product; TB, tuberculosis; DOTS, directly observed treatment strategy. 
bSource: ministries of health in each region. ity. A clinical information form was developed, based on
recommendations by the WHO and IUATLD (8), to collect
basic demographic, socioeconomic, and medical informa-
tion. Particular attention was paid to questions that would
clarify previous TB treatment for each patient. Questions
were included about previous hospitalization and about
which anti-TB drugs the patient may have taken. Previous
TB treatment assessed by the interview was then compared
to the patient’s previous TB treatment status as determined
through the functioning DOTS program. Any discrepan-
cies were then investigated and clarified by reinterviewing
the patients and physicians who treated their condition. In
addition, for patients from Karakalpakstan only, medical
records from the previous Soviet system of TB treatment
were checked for previous TB treatment.
New patients were defined as those who had received
no or <1 month of antituberculosis drug treatment before
diagnosis. Retreatment patients were all those previously
treated with TB drugs for >1 month. Data on the HIV sta-
tus of patients with TB are not available in this area.
Transport of Sputum Samples and Laboratory Testing
Because no local capability for culture and drug-sensi-
tivity testing exists, sputum samples were transported
directly to a supranational reference laboratory (SRL) in
Europe. Sputum specimens were shipped from both
regions separately either weekly or biweekly throughout
the survey. Samples were first transported to the regional
laboratories in each region by car. They were then flown to
the capital cities in Uzbekistan and Turkmenistan; they
were then transported as international air cargo to
Frankfurt, Germany, and on to Hamburg and the SRL in
Borstel, Germany. All international regulations pertaining
to the transport of infectious material were followed.
Sputum samples were cultured, and drug-sensitivity
testing was performed by the German SRL in Borstel.
Strains were tested for drug sensitivity to the five first-line
drugs used in the DOTS program in the Aral Sea area,
namely, isoniazid, rifampin, pyrazinamide, ethambutol,
and streptomycin. In addition, drug-susceptibility testing
for three second-line drugs was performed; susceptibility
to prothionamide was tested on all strains, whereas suscep-
tibility to capreomycin and ofloxacin was tested on all
strains, excluding the first 45 sent from both countries (24
from Uzbekistan and 21 from Turkmenistan, 11% of
strains). Strains from a small, randomly drawn sample of
patients with MDR-TB (20 isolates) and patients whose
strains were susceptible to antimicrobial drugs (10 iso-
lates) were later tested for resistance to kanamycin. 
Primary isolation and culture of mycobacterial isolates
followed standard recommendations, where specimens
were decontaminated by NALC-NaOH and added to two
solid media; Löwenstein-Jensen and Stonebrink ad
MGIT960TB (Becton-Dickinson Microbiology Systems,
Cockeysville, MD) (9). For all strains, drug-susceptibility
testing was performed on Löwenstein-Jensen media by the
proportion method. If growth was insufficient, drug-sus-
ceptibility testing was performed by using the modified
proportion method in BACTEC 460TB (Becton-
Dickinson). The SRL participates in annual quality control
programs within Germany and within the WHO and
Centers for Disease Control and Prevention (CDC) SRL
network. In addition, an internal quality control system for
all techniques and media was used.
Statistical Analyses
All clinical and laboratory data were entered into a
database by using EpiInfo (6.04, CDC, Atlanta, GA). Chi-
square analysis was used for comparisons of proportions.
Logistic regression analysis was performed to identify
variables independently associated with MDR-TB (SPSS
version 10.0, SPSS Inc., Chicago, IL). Cluster sampling
was taken into account through use of the Fleiss quadratic
approximation in calculating 95% CL for the proportions
of MDR-TB in the sample. Separate design effects were
calculated for each region.
Results
Recruitment of Patients 
Patient recruitment began in July 2001 in both regions
and was completed by the end of January 2002 in
Karakalpakstan and March 2002 in Dashoguz. In total, 441
patients were enrolled in the study, 213 from Dashoguz
and 228 from Karakalpakstan. Overall, 76% of eligible
patients were recruited in Dashoguz and 68% in
Karakalpakstan. The main reasons patients were not
enrolled were the following: refusal to participate (13% in
Karakalpakstan and 3% in Dashoguz), patient default
before treatment (8% in both Karakalpakstan and
Dashoguz), and logistic constraints in the timely collection
and transport of sputum samples (9% in Karakalpakstan
and 2% in Dashoguz). Other reasons for nonparticipation
in the study included the following: unable to produce an
additional adequate sputum sample (5% in Dashoguz),
patient imprisonment after diagnosis (3% in Dashoguz),
and patient transfer out of the program after diagnosis. The
relative biases introduced by these reasons for nonpartici-
pation are unknown; however, the high rate of refusal to
participate in Karakalpakstan was mostly due to inade-
quate patient communication in the early stages of the sur-
vey and is therefore unlikely to have affected the
representativeness of the sample.
Laboratory Culture Results
All 441 sputum samples were sent to SRL in Borstel,
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416 samples (213 from Karakalpakstan and 203 from
Dashoguz). Overall, 12 (2.7%) of the 441 samples were
found to be contaminated, and an additional 11 (2.5%)
could not be cultured. Other than M. tuberculosis, two
other strains of Mycobacterium (one M. bovis and one M.
fortuitum) were grown.
Demographics of the Study Population 
For the purposes of analysis, only patients for whom a
valid culture for M. tuberculosis was obtained were includ-
ed. The final sample consisted of 106 new patients and 107
retreatment patients in Karakalpakstan and 105 new cases
and 98 retreatment cases in Dashoguz. Patients ranged in
age from 11 years to 77 years, with a mean of 34 years and
a median of 31 years. The mean age was slightly but non-
significantly higher in retreatment patients. Overall, 60%
of the patients in the study sample were male, with more
men among retreatment cases than new cases (65% vs.
55%). Overall 53% of all patients with positive smears
registered in the DOTS program in the year 2002 in
Karakalpakstan and Dashoguz were male.
Considerably more single men than single women lived
in both regions; overall, 19% of women and 40% of men
were single. Approximately 70% of all patients, both men
and women in both countries, reported at least 10 years of
education. No women reported previous imprisonment,
whereas 25% of men in Dashoguz and 36% of men in
Karakalpakstan reported being in prison at some stage dur-
ing their lives. 
First-line Anti-TB Drug Resistance
Results on resistance to the five first-line drugs tested
are given in Tables 2 and 3. In Karakalpakstan, the strains
of 52% of new patients and 20% of retreatment patients
were fully sensitive to all five first-line drugs. In
Dashoguz, strains from 70% of new patients and 38% of
retreatment patients were sensitive to the five first-line
drugs. The most notable monoresistance (resistance to just
one first-line drug) was seen for streptomycin in both
regions (in 11% of all Karakalpakstan patients and in 14%
of Dashoguz patients). Similarly, streptomycin showed the
highest levels of drug resistance overall; strains from 58%
of all patients in Karakalpakstan and from 37% of patients
in Dashoguz were resistant to streptomycin. Major resist-
ance to isoniazid also occurred, with 53% of all patients in
Karakalpakstan and 31% in Dashoguz infected with resist-
ant strains. Resistance to rifampin was closely correlated
to multidrug resistance; only one patient had a strain that
was resistant to rifampin without also being resistant to
isoniazid.
Levels of MDR-TB were high; overall, 27% (95% CL
15% to 42%) of all positive smears from patients starting
DOTS treatment were infected with MDR-TB strains in
Karakalpakstan and 11% (95% CL 7% to 17%) in
Dashoguz. The proportion of MDR-TB was higher in
Karakalpakstan than in Dashoguz for both new and retreat-
ment cases; 13% (95% CL 4% to 35%) versus 4% (95%
CL 1% to 11%) for new cases and 40% (95% CL 21% to
62%) versus 18% (95% CL 11% to 28%) for retreatment
cases. 
Second-line Anti-TB Drug Resistance
Resistance results to the three second-line drugs first
tested are shown in Table 4. Of these three drugs tested on
most strains, clinically significant resistance was shown
only to prothionamide, with 16% resistance among MDR-
TB cases in Karakalpakstan and 9% in Dashoguz.
Kanamycin was tested on a randomly drawn sample of
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Table 2. First-line anti-tuberculosis drug resistance results, 
Karakalpakstan, Uzbekistan
a 
  No. new  
cases (%) 
No. retreatment 
cases (%)  Total no. (%) 
Total tested  106  107  213 
Any resistance  51 (48.1)  86 (80.4)  137 (64.3) 
Monoresistance       
H only  3 (2.8)  7 (6.5)  10 (4.7) 
R only  0  0  0 
E only  0  0  0 
S only  12 (11.3)  11 (10.3)  23 (10.8) 
Z only  0  1 (0.9)  1 (0.5) 
H and R resistance       
MDR  14 (13.2)  43 (40.2)  57 (26.8) 
HR only  0  1 (0.9)  1 (0.5) 
HRE only  0  0  0 
HRS only  4 (3.8)  10 (9.3)  14 (6.6) 
HRZ only  0  0  0 
HRES only  6 (5.7)  19 (17.8)  25 (11.7) 
HREZ only  0  0  0 
HRSZ only  1 (0.9)  0  1 (0.5) 
HRESZ  3 (2.8)  13 (12.1)  16 (7.5) 
H + other resistance       
HE only  0  0  0 
HS only  13 (12.3)  15 (14.0)  28 (13.1) 
HZ only  1 (0.9)  1  2 (0.9) 
HES only  2 (1.9)  4 (3.7)  6 (2.8) 
HEZ only  0  0  0 
HSZ only  1 (.9)  3 (2.8)  4 (1.9) 
HESZ only  5 (4.7)  1 (0.9)  6 (2.8) 
R + other resistance       
RE only  0  0  0 
RS only  0  0  0 
RZ only  0  0  0 
RES only  0  0  0 
RESZ only  0  0  0 
Any drug resistance       
Any H resistance  39 (36.8)  74 (69.2)  113 (53.1) 
Any R  resistance  14 (13.2)  43 (40.2)  57 (26.8) 
Any E resistance  16 (15.1)  37 (34.6)  53 (24.9) 
Any S resistance  47 (44.3)  76 (71.0)  123 (57.7) 
Any Z resistance  11 (10.4)  19 (17.8)  30 (14.1) 
aH, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z, pyrizinamide. 20 previously identified MDR-TB isolates and 10 non-
MDR-TB isolates from two districts in Karakalpakstan.
Two of the MDR-TB isolates showed resistance to
kanamycin (10%), whereas none of the 10 non-MDR-TB
strains showed resistance.
Factors Associated with MDR-TB
To investigate factors associated with the high rates of
MDR-TB, a multivariable logistic regression analysis was
conducted with MDR-TB as the dependent variable. The
following factors were entered into the model: sex, previ-
ous TB treatment, previous imprisonment, unemployment,
alcohol use, and region. Factors significantly predicting
MDR-TB in the model were previous TB treatment,
region, and female sex (Table 5). Although a large propor-
tion of male patients reported previous imprisonment, this
factor was not significant on either univariate or multivari-
able analysis.
Since previous TB treatment is the strongest factor
associated with MDR-TB, the logistic regression was
repeated, including only new patients from both regions.
Both female gender (OR 7.8, 95% CL 1.7 to 36.3) and
region (OR 3.8, 95% CL 1.2 to 12.4) remained significant
predictors of MDR-TB.
Clearly, the most notable factor predicting MDR-TB is
previous TB treatment. Most retreatment patients in both
regions reported only one previous episode of treatment,
60% in Karakalpakstan and 66% in Dashoguz. In addition,
most retreatment patients were not previously treated
under DOTS, 83% in Karakalpakstan and 75% in
Dashoguz. Of those that received previous DOTS treat-
ment, 50% were new patients before their previous DOTS
treatment. These patients had levels of MDR-TB similar to
retreatment patients overall (Karakalpakstan, 3/8, 38%;
Dashoguz, 2/15, 13%). Those that received DOTS treat-
ment in addition to previous non-DOTS TB treatment had
higher rates of MDR-TB (Karakalpakstan, 6/8, 75%;
Dashoguz, 7/14, 50%).
Discussion
This survey has shown extremely high rates of MDR-
TB in regions of two countries in Central Asia, although
the confidence intervals are large because of the small
sample size and cluster sampling. These findings, along
with similar data from other regions, suggest that the for-
mer Soviet Union is one large hot spot for MDR-TB.
Because of logistic constraints, sampling was restricted
to four districts implementing DOTS in each of the two
regions. These districts were not randomly selected.
However, as sampling was sequential, the final sample is
representative of patients with positive smears whose
cases were diagnosed in these districts. The DOTS strate-
gy was implemented in the Aral Sea area, starting in the
districts most affected by the environmental degradation.
These districts are more economically deprived and there-
fore may have higher rates of TB incidence. However, we
have no reason to suspect that the prevalence of drug
resistance is different in neighboring districts. Drug resist-
ance may well increase as patients are increasingly able to
purchase drugs privately and use them sporadically. In
addition, patients who refused DOTS treatment and those
defined as having chronic TB were not included in the sur-
vey. These patients are more likely to have had previous
erratic TB treatment and therefore may be more likely to
harbor drug-resistant strains. If this were the case, then the
figures presented here are an underestimate of the situa-
tion.
In this survey, careful attention was paid to the differ-
entiation of new and retreatment patients. A retrospective
Multidrug-resistant Tuberculosis in Central Asia
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cases(%)  Total no. (%) 
Total tested  105  98  203 
Any resistance  32 (30.5)  61 (62.2)  93 (45.8) 
Monoresistance       
H only  6 (5.7)  8 (8.2)  14 (6.9) 
R only  0  1 (1.0)  1 (0.5) 
E only  0  0  0 
S only  16 (15.2)  13 (13.3)  29 (14.3) 
Z only  0  0  0 
H and R resistance       
MDR  4 (3.8)  18 (18.4)  22 (10.8) 
HR only  0  0  0 
HRE only  0  0  0 
HRS only  3 (2.9)  7 (7.1)  10 (4.9) 
HRZ only  0  0  0 
HRES only  1  6 (6.1)  7 (3.4) 
HREZ only  0  0  0 
HRSZ only  0  3 (3.1)  3 (1.5) 
HRESZ  0  2 (2.0)  2 (1.0) 
H + other resistance       
HE only  0  1 (1.0)  1 (0.5) 
HS only  5 (4.8)  10 (10.2)  15 (7.4) 
HZ only  0  1 (1.0)  1 (0.5) 
HES only  1 (1.0)  6 (6.1)  7 (3.4) 
HEZ only  0  0  0 
HSZ only  0  3 (3.1)  3 
HESZ only  0  0  0 
R + other resistance       
RE only  0  0  0 
RS only  0  0  0 
RZ only  0  0   
RES only  0  0  0 
RESZ only  0  0  0 
Any drug resistance       
    Any H resistance  16 (15.2)  47 (48.0)  63 
    Any R resistance  4 (3.8)  19 (19.4)  23 
    Any E resistance  2 (1.9)  15 (15.3)  17 
    Any S resistance  26 (24.8)  50 (51.0)  76 
    Any Z resistance  0  9 (9.2)  9 
aH, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z,  pyrizinamide. review of pre-DOTS medical records in Karakalpakstan
showed only one misclassified patient, among the 213
included. As well, in the Aral Sea area DOTS program, all
patients in whom active TB is diagnosed have the opportu-
nity to receive DOTS treatment, regardless of previous
treatment status. Thus, no motivation or incentive exists
for patients or doctors to misrepresent their previous TB
treatment status, as has been suggested elsewhere (10).
Nevertheless, some misclassification is possible but is not
expected to greatly alter the high proportions of MDR-TB
seen among new patients, particularly in Karakalpakstan.
These levels of MDR-TB indicate the likely transmission
of multidrug-resistant strains. 
Testing showed some second-line drug resistance, par-
ticularly for prothionamide, among MDR-TB strains. The
regions in our study are poorer and more isolated than
other parts of both countries and other areas in the former
Soviet Union, which possibly spares them from the high
rates of second-line drug resistance seen in other areas
(11). Although not all strains were tested for second-line
resistance, the sample is still representative because only
the first 11% of strains (Karakalpakstan and Dashoguz,
respectively) from patients sequentially recruited into the
survey were not tested for capreomycin and ofloxacin, and
no systematic differences were found between the strains
from first patients and strains from latter patients.
The difference in levels of TB drug resistance between
the two regions that are geographically adjacent but sepa-
rated by a national border provides clues regarding the
emergence of drug resistance. Since gaining independence
from the former Soviet Union, most Central Asian states
have experienced a substantial decline in healthcare serv-
ices (12). In Uzbekistan, during the 1990s, the gross
domestic product (GDP) declined considerably as has the
percentage of GDP spent on health (13). Turkmenistan
fared somewhat better financially because of its consider-
able oil and gas wealth; it has a per capita GDP almost
double that of Uzbekistan (6), with a relatively stable per-
centage spent on health (14). 
These declines in healthcare spending in both countries
have resulted in intermittent shortages of most first-line
anti-TB drugs. Local TB physicians in Karakalpakstan
(Uzbekistan) estimate that before the DOTS program start-
ed, nearly 50% of patients had their treatment interrupted
because of problems with drug supply. Additionally,
because of the lack of drugs, patients were often requested
to purchase drugs themselves after they left the hospital for
the continuation phase at home. Many patients likely could
not afford all drugs and therefore purchased what they
could, resulting again in treatment interruptions. High
streptomycin resistance attests to the widespread use of
this popular injectable antimicrobial agent, often as a short
monotherapy course. Although drug shortages have been
reported over the last decade in Turkmenistan, they likely
affected an overall lower percentage of patients, which
explains the lower rate of drug resistance seen in
Dashoguz.
The extent to which drug resistance existed before the
collapse of the Soviet Union is unknown. The Soviet sys-
tem hospitalized TB patients for long periods, with conse-
quently high levels of interruption and default. In addition,
treatment regimens using combinations of all first-line and
some second-line drugs were not standardized (1). These
conditions may have contributed to a baseline level of
resistance from which the notable level of MDR-TB
shown here has emerged. Most retreatment patients were
not previously treated under DOTS; thus, our results can-
not be attributed to the implementation of DOTS.
Elsewhere in the former Soviet Union, high rates of
MDR-TB have been seen among prisoner populations
(15). Although a high proportion of patients in our study
reported previous imprisonment, no greater level of MDR-
TB was seen among these patients. This finding suggests
that MDR-TB is not confined to specific sectors of the
population, such as prisoners, but is a problem affecting
the general community. Of particular concern in this area
is the high rate of out-migration attributable to worsening
environmental and socioeconomic conditions (16; unpub.
data, Médecins Sans Frontières, 2002), which can lead to
international transmission of MDR-TB. 
The finding of a greater risk for MDR-TB among
women, independent of previous TB treatment status, is
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Table 4. Second-line drug resistance results  
New  Retreatment  MDR-TB
b   
  Total  Resistant (%)  Total  Resistant (%)  Total  Resistant (%) 
Karakalpakstan (Uzbekistan) 
Prothionamide  106  7 (7)  107  11 (10)  57  9 (16) 
Capreomycin  88  1 (1)  101  1 (1)  56  1 (2) 
Ofloxacin  88  2 (2)  101  4 (4)  56  1 (2) 
Dashoguz (Turkmenistan) 
Prothionamide  105  1 (1)  98  4 (4)  22  2 (9) 
Capreomycin  89  0  93  0  21  0 
Ofloxacin  89  0  93  0  21  0 
aAll strains were tested for prothionamide; a representative subset of these were tested for both capreomycin and ofloxacin. 
bMDR-TB, multidrug-resistant tuberculosis. important and confirms similar findings in Archangels
Oblast in Russia (17) and Estonia (18). In the Aral Sea
area, women make up slightly less than 50% of all patients
with positive smears registered in the DOTS program. This
statistic suggests a greater susceptibility to drug-resistant
TB and warrants further research.
Clearly, such high rates of MDR-TB as seen in both
Karakalpakstan, Uzbekistan, and Dashoguz, Turkmen-
istan, are a substantial threat to TB control. Standardized
treatment with first-line, through drugs implementing the
DOTS strategy, would be expected to result in poor out-
comes for more than one fourth of patients with positive
smears in Karakalpakstan (19) and would render the WHO
target of 85% success unattainable. These patients will
remain infectious for long periods, with the resultant risk
of transmitting drug-resistant strains. WHO suggests that
high levels of MDR-TB (>3% among new cases) warrant
the direct management of MDR-TB to contain transmis-
sion and reduce the high incidence and costs of this disease
(20).
DOTS treatment on its own may well stop the produc-
tion of more MDR-TB, but it is unlikely to reduce high
levels of existing drug resistance (21). Effective treatment
of all cases of TB is required to prevent transmission.
MDR-TB treatment is expensive and lengthy, and the pool
of those with expertise treating MDR-TB is limited. Asim-
pler, more affordable, and more effective treatment strate-
gy is required; however, until this exists, patients require
treatment with existing strategies. As a result of this sur-
vey, Médecins Sans Frontières has decided to launch a
pilot DOTS-Plus MDR-TB treatment project in
Karakalpakstan because the cost of inaction will be high. 
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